Study of the effect of serelaxin on high-sensitivity cardiac troponin I (hs cTnI) release in patients with chronic heart failure

Registry ID

EUCTR2015-002673-38

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Novartis Pharma Services AG

Start date

2015-10-29

Completion date

2017-04-19

Last update

2026-08-16

Conditions

• Chronic Heart Failure

Summary

To evaluate the effect of short-term i.v. administration of serelaxin in CHF patients on the geometric mean of hs-cTnI concentrations compared to placebo (both in addition to SoC) after an exercise testing session.

Locations

• , , Germany
• , , UK

Related clinical trials

• The HEARTFELT Study
• A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions
• Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
• The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)
• Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
• Mobile-Based Telemedicine and Health-Related Quality of Life Among Patients With Chronic Heart Failure (MOBILE-HF)

View on source registry